Repare Therapeutics announced the first patient has been dosed in the company’s Phase 1 LIONS clinical trial evaluating RP-1664, a highly selective, oral polo-like kinase 4 inhibitor, for the monotherapy treatment of adult and adolescent patients enriched for TRIM37-high solid tumors.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on RPTX:
- Repare Therapeutics price target lowered to $10 from $25 at H.C. Wainwright
- Repare Therapeutics Regains Rights, Ends Roche Agreement
- Repare Therapeutics to regain global rights to Camonsertib
- Repare Therapeutics Receives Milestone Payment from Roche
- Capital One says buy these six biotech stocks for 2024
